Neogen Corp (NEOG) · Oct 6, 2026 · Earnings
Beat — adj. EPS $0.08 vs ~$0.05 consensus; revenue $222.8M vs ~$208.2M
Neogen’s Q1 earnings beat expectations, margins improved, and FY27 guidance rose modestly as Petrifilm manufacturing moves toward launch.
Neogen is rebuilding its post-3M Food Safety platform around stronger execution, internal Petrifilm manufacturing, and a more focused food-safety portfolio; the Genomics divestiture is also still pending. The 3M integration and Petrifilm transition remain the central operational issues in the business.
The quarter beat the published benchmark by a meaningful margin. Revenue reached $222.8 million versus roughly $208.2 million expected, while adjusted EPS was $0.08 versus approximately $0.05 consensus. That is a cleaner positive signal than the GAAP result alone suggests: reported net income was a $11.9 million loss, but the prior-year quarter included a $76.4 million non-cash gain from the Cleaners & Disinfectants divestiture.
| Metric | Q1 FY27 | Q1 FY26 / expectation | Read |
|---|---|---|---|
| Revenue | $222.8M | $209.2M prior year; ~$208.2M consensus | Beat |
| Core revenue growth | 8.1% | — | Underlying growth remained solid |
| Adjusted EPS | $0.08 | $0.04 prior year; ~$0.05 consensus | Beat |
| Adjusted EBITDA | $41.6M | $35.5M prior year | Improved |
| Adjusted EBITDA margin | 18.7% | 17.0% prior year | Expanded |
| FY27 revenue guidance | $885M–$890M | $880M–$885M prior | Raised |
| FY27 adjusted EBITDA guidance | $181M–$183M | $180M–$182M prior | Raised |
The improvement is operational, not just accounting noise. Food Safety grew 7.4% and Animal Safety grew 4.2%, with both segments posting 8%-plus core growth. Adjusted EBITDA rose 17% year over year as higher revenue created operating leverage, while adjusted gross margin increased only modestly to 49.8%, so the quarter shows better execution but not yet a dramatic structural margin reset.
The guidance raise confirms momentum but is deliberately modest. The revenue midpoint increased by $5 million and the adjusted EBITDA midpoint by $1 million, which is an upgrade rather than a wholesale change in the outlook. The company is also flagging that roughly 3% of core growth benefited from distributor inventory adjustments and order timing, limiting how much of the reported growth should be treated as durable demand.
Petrifilm execution is the key business-specific validation. Neogen completed full validation of its first SKU and still expects the multi-quarter move to Lansing to begin in November 2026, reducing dependence on the former manufacturing arrangement if the rollout stays on schedule. That milestone was partly anticipated from prior updates, but successful validation lowers an important execution risk. 〔0〕
Bottom line: This is a genuine earnings beat with a modest guidance lift and tangible progress on Neogen’s most important manufacturing transition. The result advances the turnaround story, although some growth benefited from timing and the larger proof point—sustained Petrifilm production—still lies ahead.
Petrifilm manufacturing transition begins in November 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!